OnADose

Name: OnADose
Rating: 5 (3 reviews)
Author: AbbVie

Medical

Only for iPhone

Free · Designed for iPhone

3 Ratings
Ages

13+
Years
Category

Medical
Developer

AbbVie
Language

EN
English
Size

46.5
MB

iPhone

OnADose is an onabotulinumtoxinA dosing and reconstitution educational tool for spasticity, cervical dystonia, and chronic migraine. This app is intended for training use by US healthcare professionals ONLY. Patients should seek a doctor’s advice before making any medical decisions. OnabotulinumtoxinA Important Safety Information OnabotulinumtoxinA Indications Chronic Migraine -OnabotulinumtoxinA is indicated for the prophylaxis of headaches in adult patients with Chronic Migraine (≥ 15 days per month with headache lasting 4 hours a day or longer). Limitations of Use -Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies. Spasticity -OnabotulinumtoxinA is indicated for the treatment of spasticity in patients 2 years of age and older. Limitations of Use -OnabotulinumtoxinA has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture. Cervical Dystonia -OnabotulinumtoxinA is indicated for the treatment of adults with Cervical Dystonia to reduce the severity of abnormal head position and neck pain associated with Cervical Dystonia. IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of onabotulinumtoxinA and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. Contraindications -Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation -Infection at the proposed injection site Warnings and Precautions -Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur -Potency Units of onabotulinumtoxinA are not interchangeable with other preparations of botulinum toxin products -Potential serious adverse reactions after onabotulinumtoxinA injections for unapproved uses -Concomitant neuromuscular disorder may exacerbate clinical effects of treatment -Use with caution in patients with compromised respiratory function -Bronchitis and upper respiratory tract infections in patients treated for spasticity Adverse Reactions The most common adverse reactions (≥5% and >placebo, if applicable) are: -Chronic Migraine: neck pain, headache -Adult Spasticity: pain in extremity -Pediatric Spasticity: upper respiratory tract infection -Cervical Dystonia: dysphagia, upper respiratory infection, neck pain, headache, increased cough, flu syndrome, back pain, rhinitis Drug Interactions -Patients receiving concomitant treatment of onabotulinumtoxinA and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of onabotulinumtoxinA may be potentiated Use in Specific Populations -Pregnancy: Based on animal data, may cause fetal harm Please see full Prescribing Information for onabotulinumtoxinA. Available at http://www.rxabbvie.com. Copyright ©2022 AbbVie. All rights reserved.